Document is current
Any future updates will be listed below
-
Authors
Zhu, Yao https://orcid.org/0000-0003-2969-036X
Liu, Hongcai https://orcid.org/0000-0003-3846-3687
Wang, Fuqiang https://orcid.org/0000-0003-2786-0513
Li, Minjie https://orcid.org/0000-0003-1336-4009
Wang, Nana https://orcid.org/0000-0002-3776-4288
Zhan, Shuyue https://orcid.org/0009-0001-9456-7862
Sun, Wenjie https://orcid.org/0009-0006-0252-7377
Li, Shengxi
Wang, Xun https://orcid.org/0000-0001-5172-0305
Wang, Lin
Zhang, Lianjun https://orcid.org/0000-0001-9448-7718
Gu, Zhimin https://orcid.org/0000-0001-8150-2560
- License Information
-
More Information
Article History
Received: 30 October 2025
Revised: 6 May 2026
Accepted: 5 June 2026
First Online: 13 June 2026
Competing interests
: The authors declare no competing interests.
: All animal experimental protocols were approved by the ISM Institutional Animal Care and Use Committee (ISM-IACUC-0160-R). The use of human primary AML cells was approved by the Medical Ethics Committee of the First Affiliated Hospital of Soochow University (20251254), and written informed consent was obtained from all participants. All methods were performed in accordance with the relevant guidelines and regulations.
